Scancell Holdings plc (AIM:SCLP)
23.45
+1.45 (6.59%)
May 26, 2026, 4:22 PM GMT
Scancell Holdings Employees
Scancell Holdings had 60 employees as of April 30, 2025. The number of employees decreased by 1 or -1.64% compared to the previous year.
Employees
60
Change (1Y)
-1
Growth (1Y)
-1.64%
Revenue / Employee
78.52K GBP
Profits / Employee
-91.85K GBP
Market Cap
238.69M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Apr 30, 2025 | 60 | -1 | -1.64% |
| Apr 30, 2024 | 61 | 10 | 19.61% |
| Apr 30, 2023 | 51 | 11 | 27.50% |
| Apr 30, 2022 | 40 | 15 | 60.00% |
| Apr 30, 2021 | 25 | 3 | 13.64% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Oxford Nanopore Technologies | 1,316 |
| Oxford Biomedica | 977 |
| hVIVO | 376 |
| Avacta Group | 151 |
| 4basebio | 110 |
| PureTech Health | 56 |
| Faron Pharmaceuticals Oy | 33 |
| Hemogenyx Pharmaceuticals | 16 |
Scancell Holdings News
- 4 weeks ago - FDA Grants Fast Track Designation To Scancell For ISCIB1+ In Treating Advanced Melanoma - Nasdaq
- 4 weeks ago - Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study - GlobeNewsWire
- 4 months ago - Scancell Holdings Earnings Call Transcript: H1 2026 - Transcripts
- 4 months ago - Scancell Holdings Quarterly report: H1 2026 - Filings
- 4 months ago - Scancell Holdings Slides: H1 2026 - Filings
- 4 months ago - Scancell Holdings Earnings Call Transcript: H1 2026 - Transcripts
- 4 months ago - Scancell Holdings Quarterly report: H1 2026 - Filings
- 4 months ago - Scancell Holdings Slides: H1 2026 - Filings